title: Effects of 22 CYP2D6 Genetic Variations Newly Identified in Chinese Population on Olanzapine Metabolism in vitro.
abstract: The objective of this study was to assess the catalytic activity of 22 novel CYP2D6 allelic variants (2D6*87-*98, R25Q, F164L, E215K, F219S, V327M, D336N, V342M, R344Q, R440C and R497C) to olanzapine in vitro. Their protein products expressed in Spodoptera frugiperda 21 (Sf21) insect cells were incubated with olanzapine 100-2,000 μmol/l for 30 min. The kinetic parameters of Km, Vmax and intrinsic clearance were determined by 2-hydroxymethylolanzapine, the metabolite of olanzapine mediated by CYP2D6, using ultra-performance liquid chromatography tandem mass spectrometry. Results showed that the kinetic parameters of 2 alleles, CYP2D6*92 and 2D6*96, could not be detected; 17 allelic variants, CYP2D6*87-*88, 2D6*90-*91, 2D6*93-*95, 2D6*97, R25Q, F164L, E215K, F219S, V327M, V342M, R344Q, R440C and R497C, significantly reduced the intrinsic clearance of olanzapine; 2 variants, CYP2D6*89 and 2D6*98, increased the intrinsic clearance of olanzapine; no difference was found in intrinsic clearance of D336N. Furthermore, 6 alleles, CYP2D6*87, 2D6*88, 2D6*91, 2D6*93, 2D6*97 and R497C, exhibited higher Km values in a range of 120.80-217.56% relative to wild-type CYP2D6*1. The research demonstrated the metabolic phenotype of the 22 novel CYP2D6 variants for olanzapine that were different from probe drugs we used previously and might provide beneficial information to the personalized medicine of olanzapine.
authors.affiliation: Department of Pharmacology, School of Pharmacy, Wenzhou Medical University, Wenzhou, China.
authors.forename: Hong-Yu
authors.initials: HY
authors.lastname: Zhou
authors.forename: Er-Min
authors.initials: EM
authors.lastname: Gu
authors.forename: Qiu-Lei
authors.initials: QL
authors.lastname: Chen
authors.forename: Yun-Yun
authors.initials: YY
authors.lastname: Zhan
authors.forename: Shuang-Hu
authors.initials: SH
authors.lastname: Wang
authors.forename: Bing-Qing
authors.initials: BQ
authors.lastname: Liang
authors.forename: Da-Peng
authors.initials: DP
authors.lastname: Dai
authors.forename: Jian-Ping
authors.initials: JP
authors.lastname: Cai
authors.forename: Guo-Xin
authors.initials: GX
authors.lastname: Hu
mesh_terms: D014150:Antipsychotic Agents / Q000378:metabolism*; D044466:Asian People / Q000235:genetics*; D001569:Benzodiazepines / Q000378:metabolism*; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D004305:Dose-Response Relationship, Drug; D014644:Genetic Variation / Q000235:genetics*; D006801:Humans; D000077152:Olanzapine; D011110:Polymorphism, Genetic / Q000235:genetics; D011159:Population Surveillance / Q000379:methods
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D019389:Cytochrome P-450 CYP2D6; D000077152:Olanzapine